SEC 13F Intelligence

Venbio Partners LLC / AKRO

Venbio Partners LLC’s Akero Therapeutics Inc Com Position

Does Venbio Partners LLC own Akero Therapeutics Inc Com (AKRO)? Not currently — the last reported position was 596.5K shares worth $20M in Q3 2022; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$20M
Q3 2022
Shares
596.5K
% of Portfolio
+4.70%
Quarters Held
13
position exited

Position History AKRO

Reported value by quarter
Q2 ’19: $76MQ2 ’19Q3 ’19: $90MQ4 ’19: $87MQ4 ’19Q2 ’20: $78MQ3 ’20: $75MQ3 ’20Q4 ’20: $63MQ1 ’21: $71MQ1 ’21Q2 ’21: $55MQ3 ’21: $49MQ3 ’21Q4 ’21: $46MQ1 ’22: $31MQ1 ’22Q2 ’22: $21MQ3 ’22: $20MQ3 ’22filingsflow.com
QuarterSharesValue% of Portfolio
Q3 2022596.5K$20M+4.70%
Q2 20222.17M$21M+5.84%
Q1 20222.17M$31M+6.83%
Q4 20212.17M$46M+8.28%
Q3 20212.20M$49M+4.90%
Q2 20212.20M$55M+6.44%
Q1 20212.44M$71M+6.74%
Q4 20202.44M$63M+5.57%
Q3 20202.44M$75M+11.44%
Q2 20203.15M$78M+65.27%
Q4 20193.94M$87M+37.50%
Q3 20193.95M$90M+42.68%
Q2 20193.95M$76M+33.61%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Venbio Partners LLC’s full portfolio or all institutional holders of AKRO.